Emaglif

Composition: Empagliflozin

Form: Film-coated tablets

Indications: Type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control (as monotherapy or in combination with other oral hypoglycemic agents and/or insulin); in patients with T2DM and cardiovascular disease and/or chronic kidney disease to reduce cardiovascular mortality and hospitalizations due to heart failure.

Contraindications: Type 1 diabetes, diabetic ketoacidosis, pregnancy and lactation, severe renal impairment (eGFR < 45 mL/min/1.73 m²), age under 18 or over 85, hereditary lactose or glucose-galactose malabsorption disorders, hypersensitivity to components.

Dosage: Orally once daily, regardless of food intake: 10 mg. If glycemic control is insufficient, may increase to 25 mg once daily. Maximum dose — 25 mg/day.

Side effects: Common — genital infections (vaginal candidiasis, balanitis), urinary tract infections, frequent urination; uncommon — hypovolemia, hypotension; very common (with sulfonylureas or insulin) — hypoglycemia; common — skin itching.

Interactions: May enhance the effects of thiazide and loop diuretics (risk of dehydration), and hypoglycemia risk when combined with insulin or sulfonylureas (adjust their dose if needed).

Warnings: In elderly patients (>75 years), the risk of dehydration and urinary tract infections is increased. Use with caution if signs of dehydration or significant fluid loss are present.

Age restrictions: 18 to 85 years

Pregnancy: Contraindicated during pregnancy and breastfeeding.

Country of origin: Bangladesh

Manufacturer: ARISTOPHARMA LTD.

Storage conditions: Store in a dry, light-protected place at temperatures up to 30°C. Do not freeze. Keep out of reach of children.